Tom Powles: Positive R3 trial for PD-1 in Non-Muscle Invasive Bladder Cancer
Tom Powles, Professor at the University of London, posted on X:
“Big news.
A positive R3 trial for PD-1 in NMIBC! The CREST trial evaluated sasanlimab (PD-1i) + BCG vs Standard BCG (induction and maintenance) in BCG-naïve, high-risk NMIBC. The study met its primary endpoint of EFS with ‘clinically meaningful’ results.”
Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer. Tom also serves as the Editor-in-Chief of Annals of Oncology.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023